HEOR Analyst / Market Access

Core responsibility: an HEOR professional builds the economic and clinical evidence that determines whether a treatment gets reimbursed, while Market Access turns that evidence into an actual pricing and adoption strategy.

In practice, this means synthesizing published clinical and economic evidence through systematic literature review, building cost-effectiveness models comparing a treatment against existing alternatives, compiling value dossiers for payers, and presenting findings to health technology assessment (HTA) bodies and internal pricing teams. An HEOR Analyst working on a new oncology drug, for example, might spend weeks building an economic model showing how the drug's cost compares to existing standard-of-care treatments, then present that model to an internal pricing committee deciding the drug's India launch price.

What an HEOR professional is not: this is not a sales or marketing role, and it is not the same as clinical research, which focuses on whether a treatment works rather than whether it is worth its cost. HEOR professionals rarely interact with patients directly; their audience is payers, regulators, and internal commercial teams.

Preferred backgrounds: an advanced degree (M.Sc. or higher) in health economics, public health, epidemiology, pharmacy, or life sciences, with PhDs common at senior levels.

Acceptable backgrounds: M.Pharm graduates with an economics or research focus, or MPH graduates, are commonly hired at entry to mid levels.

Rare but possible: candidates from a purely clinical background occasionally transition in after building modeling and literature review skills separately.

Experience requirements: foundational modeling skills and systematic review experience, even through academic dissertation work, are what most entry-level hiring managers actually screen for.

Fresher pathway: possible, particularly for candidates with strong Excel-based modeling skills and dissertation-level systematic review experience, though this is a more competitive entry point than operational clinical roles.

What separates professionals who move quickly into Specialist and Manager roles is not modeling skill alone, but the ability to connect an economic model's output to a genuinely persuasive pricing or reimbursement narrative that a payer will actually act on.

The short version: HEOR is about proving whether a treatment is worth what it costs, while RWE is about proving what actually happens with it in the real world. In India, the two functions overlap so heavily that many job postings blend both under one title.

Entry-level HEOR Analyst or Associate roles in India typically start between ₹5 and 9 LPA, according to multiple independent industry sources. With 4 to 8 years of experience and specialization in health economics, real-world evidence, or market access, professionals move into the ₹12 to 20 LPA range. Senior managers, directors, and HEOR leaders, particularly at multinational pharma companies with strong global market access functions, can earn ₹25 LPA and above. Internationally, this is one of the more globally benchmarked non-clinical fields, with US HEOR Analyst salaries averaging around $72,000 annually, typically ranging from $49,500 to $92,000 depending on experience and employer.

The typical ladder runs: Analyst or Associate, then Specialist, then Manager, then Director of HEOR/Market Access.

If you are coming from a life sciences, pharmacy, or public health background and want to know whether HEOR or Market Access is the better fit for your specific strengths, book a 1:1 session with us.

Real World Evidence Scientist

Health Economist

Biostatistician

Medical Writer

AI is increasingly used to accelerate the most time-consuming part of HEOR work, systematic literature review and evidence synthesis, which traditionally takes weeks of manual screening.

This is shifting entry-level work away from pure literature-search mechanics and toward evidence interpretation and modeling judgment, since AI tools can now surface relevant studies far faster than a human reviewer working through databases manually.

What remains fundamentally human is the judgment behind connecting an economic model's output to a persuasive, defensible pricing or reimbursement recommendation a payer will actually act on. For anyone entering this field, the practical takeaway is that the professionals commanding the strongest salaries are the ones combining classical health economics training with comfort using AI tools to process larger volumes of evidence faster, rather than being replaced by them.